Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The facility will manufacture tablets, capsules, and injections for the oncology segment
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Operations of Line II was stopped due to a fire incident earlier
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Subscribe To Our Newsletter & Stay Updated
